Chip stocks fall with Nvidia after data center rev disappointment
William D. Waddill, a director at Protagonist Therapeutics, Inc. (NASDAQ:PTGX), recently sold 4,000 shares of the company’s common stock. The shares were sold on March 17, 2025, at a price of $54.25 each, totaling approximately $217,000. Following this transaction, Waddill holds 13,130 shares in the company. This sale was conducted under a Rule 10b5-1 trading plan established in November 2023. With the stock trading near $54.35, analysts maintain a strong buy consensus with price targets ranging from $45 to $82. For deeper insights into PTGX’s valuation and 13 additional ProTips, check out the comprehensive research report available on InvestingPro.
In other recent news, Protagonist Therapeutics has garnered attention with its latest clinical developments. The company announced promising Phase 2b trial results for its drug candidate, rusfertide, in treating ulcerative colitis (UC), leading Truist Securities to raise its price target from $60 to $76. This follows a clinical response rate of 64% and a remission rate of 30%, surpassing previous forecasts. Meanwhile, Jefferies maintained a Buy rating with a $68 target, highlighting the successful primary and secondary endpoints achieved by Icotrokinra in UC trials. BMO Capital Markets also increased its price target to $72, driven by positive data for treatments in plaque psoriasis and UC, while maintaining an Outperform rating. H.C. Wainwright reiterated its Buy rating with a $54 target, citing compelling data on Icotrokinra’s efficacy in psoriasis. BTIG reaffirmed a Buy rating, setting a target of $73, and noted an anticipated increase in volume forecasts for Protagonist’s products in the coming years. These updates reflect a strong market interest in Protagonist’s pipeline and potential growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.